Artificial Heart Market Size & Growth Forecast 2026–2035, By Segments (Type, Therapy), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Artificial Heart Market size was valued at USD 3.41 Billion in 2025 and is anticipated to grow at a 11.2% CAGR from 2026 to 2035, reaching USD 9.86 Billion by 2035. The industry revenue for 2026 is assessed at USD 3.75 billion.

• Base Year Value (2025): USD 3.41 Billion
• CAGR (2026-2035): 11.2%
• Forecast Year Value (2035): USD 9.86 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Artificial Heart Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for 62.18% of the market in 2025, supported by advanced cardiac care infrastructure, specialized hospitals, experienced surgical teams, and consistent adoption of artificial heart therapies.
  • Asia Pacific is expected to grow at a 12.54% CAGR, driven by expanding cardiovascular treatment access, improving hospital capabilities, rising patient demand, and wider availability of specialized cardiac procedures.

• Segment Momentum:

  • LVADs accounted for a 74.3% share in 2025 due to their broad clinical adoption, established treatment role, and suitability for supporting advanced heart failure patients without complete heart replacement.
  • Destination Therapy is expanding as more patients who are not eligible for heart transplantation require long-term mechanical circulatory support as a definitive treatment option.

• Market Expansion Drivers:

  • Increasing donor heart shortage driving demand for artificial heart alternatives.
  • Rising prevalence of heart failure and aging population increasing device adoption.
  • Advancements in LVAD and total artificial heart technologies improving patient survival outcomes.

• Leading Market Participants:

  Key players in the artificial heart market include Abbott Laboratories (United States), SynCardia Systems, LLC (United States), CARMAT SA (France), ABIOMED, Inc. (United States), BiVACOR Inc. (United States), Jarvik Heart, Inc. (United States), Realheart AB (Sweden), LivaNova PLC (United Kingdom), Getinge AB (Sweden), Terumo Corporation (Japan).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 3.41 Billion
  • Projected Market Size: USD 9.86 Billion by 2035
  • Growth Forecasts: 11.2% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: LVADs (Type) | Bridge To Transplant (Therapy)
  • Emerging Opportunity Segment: Total Artificial Heart (Type) | Destination Therapy (Therapy)

Market Growth Drivers and Industry Trends

Increasing donor heart shortage driving demand for artificial heart alternatives

As the gap between patients eligible for transplantation and available donor hearts persists, treatment pathways increasingly shift toward mechanical circulatory support rather than waiting-list management alone. In the artificial heart market, this dynamic is driving demand for the market by positioning total artificial hearts and related replacement technologies as practical options for patients with end-stage heart failure who cannot secure a timely transplant. Hospitals and advanced cardiac centers respond by expanding implant capabilities, while clinicians adopt artificial heart alternatives earlier in the care pathway to stabilize high-risk patients and reduce mortality associated with prolonged donor scarcity.

Rising prevalence of heart failure and aging population increasing device adoption

A larger population living with advanced heart failure, combined with the higher cardiovascular risk profile of older adults, is steadily enlarging the pool of patients who progress beyond pharmaceutical management and require durable mechanical support. This is supporting market expansion for the artificial heart market by increasing referrals to specialized centers for device evaluation, particularly among patients who are poor transplant candidates because of age or comorbidities. The result is stronger procedural volumes and broader clinical use of artificial heart systems as care teams look for long-term options that can sustain circulation when conventional therapies lose effectiveness.

Advancements in LVAD and total artificial heart technologies improving patient survival outcomes

Improvements in device engineering, hemocompatibility, power systems, and patient management protocols have made mechanical support more clinically viable, which directly shapes physician confidence and hospital willingness to invest in these therapies. In the artificial heart market, better survival outcomes influence market adoption by shifting artificial heart technologies from highly selective rescue interventions toward more standardized treatment consideration for end-stage heart failure. As post-implant outcomes become more predictable and complication management improves, providers are more likely to recommend these systems, supporting market development through wider institutional acceptance and more consistent patient selection.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Increasing donor heart shortage driving demand for artificial heart alternatives	2.00%	High	North America, Europe	High	Near Term
Rising prevalence of heart failure and aging population increasing device adoption	1.70%	High	North America, Asia Pacific	High	Mid Term
Advancements in LVAD and total artificial heart technologies improving patient survival outcomes	1.40%	High	North America, Europe	High	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading regional position in 2025, accounting for a 62.18% share of the artificial heart market. This leadership is underpinned by the region’s advanced cardiac care infrastructure, strong concentration of specialized hospitals, and established use of high-acuity implantable and bridge-to-transplant therapies in routine clinical practice. Market activity is further strengthened by the presence of experienced surgical teams and structured patient management pathways, which support higher procedural volumes and more consistent adoption of artificial heart technologies across major care centers.

Asia Pacific is projected to register a 12.54% CAGR over the forecast period in the artificial heart market, driven by expanding access to advanced cardiovascular treatment and rising adoption of sophisticated cardiac support technologies in major urban healthcare systems. Growth is being propelled by improving hospital capabilities, increasing treatment demand linked to a larger patient base, and broader availability of specialized cardiac procedures, which together are widening the practical use of artificial heart solutions across the region.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Nascent	Nascent
Cost-Sensitive Region	Medium	High	Medium	High	High
Regulatory Environment	Restrictive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Moderate	Moderate	Moderate	Weak	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	Medium	Medium	Medium	Low	Low
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Stable	Strong	Weak	Weak

Key Country Insights

United States

Clinical Device Innovation

The U.S. artificial heart market benefits from advanced cardiovascular research, specialized hospitals, and strong medical device development. Healthcare providers in the U.S. are expanding adoption of mechanical circulatory support technologies for complex heart failure treatment pathways.

Japan

Precision Medical Engineering

Japan advances artificial heart technologies through precision engineering and collaboration between healthcare providers and medical device developers. Japanese hospitals emphasize compact device design, patient safety, and reliable long-term circulatory support solutions.

South Korea

Specialized Care Expansion

South Korea is strengthening artificial heart capabilities through investment in tertiary hospitals and advanced cardiac treatment programs. Medical institutions are expanding expertise in implant procedures and multidisciplinary patient care for severe heart failure cases.

Germany

Advanced Cardiac Programs

Germany integrates artificial heart technologies within specialized cardiovascular centers supported by strong clinical expertise. German healthcare institutions prioritize long-term device performance, surgical precision, and coordinated patient management throughout advanced cardiac care.

France

Research-Driven Adoption

France supports artificial heart deployment through clinical research initiatives and specialized cardiovascular treatment networks. French healthcare providers are focusing on evaluating innovative technologies while strengthening patient selection and post-implant monitoring practices.

Italy

Cardiac Treatment Integration

Italy continues integrating artificial heart technologies into advanced cardiac surgery and transplant programs. Italian hospitals are enhancing multidisciplinary care capabilities while supporting broader access to sophisticated mechanical circulatory support systems.

Segment Leadership and Growth Trends

  Type Segment Analysis: LVADs (Largest Segment) vs Total Artificial Heart (Fastest-Growing Segment)

LVADs held a 74.3% share of the artificial heart market in 2025, reflecting their established role in supporting patients with advanced heart failure while preserving part of the native heart’s function. This leadership is maintained through their broader clinical familiarity, wider use across treatment pathways, and practical fit for patients who need mechanical circulatory support without full heart replacement. In the artificial heart market, LVADs remain the leading type because they are more deeply embedded in care protocols and are applicable to a larger treated population than more intensive replacement-based options.

Total Artificial Heart is the fastest-growing segment in the artificial heart market as demand rises for solutions suited to patients with severe biventricular failure where partial support is not sufficient. Its momentum is being encouraged by the need for complete cardiac replacement in critical cases, especially when conventional ventricular assist approaches are not clinically adequate. Compared with LVAD-based support, Total Artificial Heart is gaining traction because it addresses a narrower but more acute treatment requirement that is becoming more visible in advanced end-stage heart disease management.

Therapy Segment Analysis: Bridge To Transplant (Largest Segment) vs Destination Therapy (Fastest-Growing Segment)

Within the artificial heart market, Bridge To Transplant accounted for the largest share in 2025, reinforced through its close alignment with established transplant pathways for patients awaiting donor availability. Its dominant position comes from the practical role artificial heart therapies play in stabilizing patients during often unpredictable waiting periods, helping maintain circulation until transplantation becomes possible. This keeps Bridge To Transplant at the center of current therapy use, especially where mechanical support is integrated into transplant-centered cardiac care.

Destination Therapy is the fastest-growing therapy segment in the artificial heart market because it serves patients who are not eligible for transplant and therefore require longer-term mechanical support as a definitive treatment approach. Growth is being shaped by the practical expansion of treatment demand beyond transplant candidates, with clinicians increasingly using artificial heart solutions for sustained management rather than temporary bridging alone. Relative to Bridge To Transplant, Destination Therapy is gaining momentum as the market responds to a broader patient pool that needs ongoing support without dependence on donor heart availability.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	LVADs, Heart-lung Machine, Total Artificial Heart	LVADs	Total Artificial Heart
Therapy	Bridge To Transplant, Destination Therapy, Bridge To Decision, Others	Bridge To Transplant	Destination Therapy

Competitive Landscape and Market Positioning

Top players in the artificial heart market:

1. Abbott Laboratories (United States)

2. SynCardia Systems LLC (United States)

3. CARMAT SA (France)

4. ABIOMED Inc. (United States)

5. BiVACOR Inc. (United States)

6. Jarvik Heart Inc. (United States)

7. Realheart AB (Sweden)

8. LivaNova PLC (United Kingdom)

9. Getinge AB (Sweden)

10. Terumo Corporation (Japan)

Advances in biomedical engineering are improving mechanical circulatory support solutions for critical care patients. Miniaturization and biocompatibility enhancements are driving next-generation device development. The artificial heart market is progressing with increasing focus on life-extending therapeutic innovations and patient-specific solutions.

Competitive Dynamics and Strategic Insights
Assessment Parameter	Assigned Scale	Scale Justification
Market Concentration	High	Few specialized firms dominate through regulatory approvals and tech leadership.
M&A Activity / Consolidation Trend	Moderate	Acquisitions bolster VAD pipelines for heart failure treatments.
Degree of Product Differentiation	High	Total and ventricular assist devices create distinct bridge-to-transplant options.
Competitive Advantage Sustainability	Durable	Clinical trials and patents maintain long-term efficacy advantages.
Innovation Intensity	High	Miniaturization and biological materials drive rapid cardiac advancements.
Customer Loyalty / Stickiness	Strong	Proven outcomes lock physicians and patients into approved devices.
Vertical Integration Level	Medium	Integration from design to implantation, outsourcing some biologics.

Industry Development/News

Company Name	Date	Key Development
BiVACOR	Nov-25	BiVACOR received U.S. FDA Breakthrough Device Designation for its titanium-based Total Artificial Heart, a significant regulatory milestone that accelerates the development and clinical review process for its biventricular heart failure technology. This recognition underscores the device's potential as a durable, long-term mechanical circulatory support solution for patients awaiting donor heart transplants.
BiVACOR	Oct-25	A patient implanted with the BiVACOR titanium Total Artificial Heart successfully maintained circulatory support for 105 days before receiving a donor heart transplant. This clinical milestone, part of the U.S. FDA Early Feasibility Study, validates the safety, performance, and durability of the device as an effective bridge-to-transplant therapy for end-stage heart failure.
Evaheart Medical Equipment	Oct-25	Evaheart launched the EVA-Pulsar ventricular assist device, marking its second artificial heart product and the fifth domestically developed technology of its kind in China. This expansion strengthens the company's cardiovascular device portfolio and reflects the growing maturity of the Chinese market in developing sophisticated mechanical circulatory support systems for advanced heart failure.
Edwards Lifesciences	Oct-25	Edwards Lifesciences expanded its structural heart portfolio through a series of strategic acquisitions and investments totaling over $1.5 billion. The portfolio additions, including companies such as Endotronix, Innovalve, and Affluent Medical, demonstrate a significant capital deployment strategy aimed at securing early-stage technologies and consolidating market positioning within the broader cardiovascular device ecosystem.
Edwards Lifesciences	Nov-25	The U.S. Federal Trade Commission successfully blocked Edwards Lifesciences' proposed $945 million acquisition of JenaValve Technology. The court’s preliminary injunction, citing concerns over reduced competition in the TAVR-AR device market, creates strategic uncertainty for Edwards and highlights the intensifying regulatory scrutiny surrounding pipeline acquisitions in the specialized cardiac medical device industry.
CARMAT	Dec-23	CARMAT successfully performed its first implant of the Aeson total artificial heart for a patient suffering from a cardiac tumor. As one of the few commercially available total artificial hearts, the device represents a critical therapeutic alternative for patients with advanced biventricular heart failure, demonstrating the company's progress in clinical implementation within the European market.
BiVACOR	Feb-24	BiVACOR secured a USD 13 million grant from the Australian Government’s Medical Research Future Fund to support its Total Artificial Heart program. This investment provides essential financial backing for the ongoing research, development, and clinical evaluation of the device as a long-term therapy option for patients facing severe, end-stage biventricular heart failure.